Case Report

Pure ovarian choriocarcinoma: report of two cases

Narges Izadi Mood\textsuperscript{a}, Nasrin Samadi\textsuperscript{a}, Parvaneh Rahimi-Moghaddam\textsuperscript{b}, Soheila Sarmadi\textsuperscript{a}, Zahra Eftekhar\textsuperscript{c}, Fariba Yarandi\textsuperscript{c}

Abstract

Pure primary ovarian choriocarcinoma is an extremely rare condition of gestational or nongestational origin. The possibility of gestational origin can be suspected by the presence of a corpus luteum of pregnancy but definite diagnosis would be based on genetic analysis. Here, we present two cases of pure ovarian choriocarcinoma in the forth decade of life with the possibility of gestational origin.

KEYWORDS: Gestational, Choriocarcinoma, Ovary.

Germ cell malignancies may represent up to 15% of ovarian cancers in Asian and African-American nations, where epithelial ovarian cancers occur less commonly.\textsuperscript{1}

Pure ovarian choriocarcinoma is extremely rare, with about 40 cases described in the English language articles.\textsuperscript{2} Choriocarcinoma may be gestational or nongestational. The gestational type arises from an ovarian pregnancy or is of metastatic origin from uterine choriocarcinoma, whereas the nongestational type is an extremely rare germ cell neoplasm. To distinguish pure nongestational choriocarcinoma of the ovary from metastatic or primary gestational choriocarcinoma, DNA polymorphism analysis is a useful method.\textsuperscript{3,4} The gestational variants are extremely sensitive to chemotherapy with overall cure rate approaching 98% in specialized centers.\textsuperscript{5} The prognosis correlates with the bulk of tumor as well as the sites and number of metastases.\textsuperscript{6} We present two cases of pure ovarian choriocarcinoma with possibility of gestational origin.

Case Report

Case 1: A 31-year-old woman, with a gestational history of G9, P1, Ab8 and L1 was admitted to Mirza Koochak Khan Hospital, Tehran, Iran in June 2001 with the symptoms and signs of acute abdomen. She had 5 years secondary infertility of unknown reason following her last abortion and gave the history of a missed menstrual period as well as 50 days of spotting. The serum \( \beta \)-hCG level was more than 1000 mIU/ml. Pelvic sonography revealed enlarged right ovary and a 2.7 cm left ovarian cyst. No abnormal finding was detected in uterus. In view of an adnexal mass along with positive pregnancy test, a possibility of ectopic pregnancy was considered. A right salpingo-oophorectomy was carried out. Gross examination of right ovary revealed a \( 7 \times 7 \times 4.5 \text{ cm}^3 \) mass with a hemorrhagic cut surface. Following thorough sampling of the ovarian mass (1 section per cm of the greatest dimension of the tumor), microscopic examination revealed characteristic histological fea-

\textsuperscript{a}Department of Pathology, Mirza Koochak Khan Hospital, Tehran University of Medical Sciences, Tehran, Iran.
\textsuperscript{b}Razi Institute for Drug Research, Iran University of Medical Sciences, Tehran, Iran.
\textsuperscript{c}Division of Oncology, Department of Obstetrics and Gynecology, Mirza Koochak Khan Hospital, Tehran University of Medical Sciences, Tehran, Iran.
\textsuperscript{*}Corresponding Author
E-mail: nizadimood@yahoo.com
Pure ovarian choriocarcinoma, composed of bilaminar structures of cytotrophoblasts and syncytiotrophoblasts with severe nuclear atypia and mitotic figures admixed with necrotic tissue. A corpus luteum of pregnancy (Figure 1) with multiple colloid bodies and calcifications was also observed (Figures 2 & 3). The patient received Etoposide/ Metotrexate/ Actinomycin D/ Cisplatin/ Etoposide (EMA-CE) regimen for treatment and serum β-hCG level decreased to 70 mIU/mL. She underwent second laparotomy for careful examination of tumoral involvement. Specimens from left ovary and omentum revealed no histologic features of malignancy. A corpus luteum cyst was detected in the left ovary. Computed tomographic scan revealed no brain or lung metastases. Serum alpha-fetoprotein (AFP) was in normal range. After the surgery, she took 4 courses of chemotherapy with EMA-CE regimen. The level of β-hCG decreased to below the cut-off value. There has been no evidence of tumor recurrence during seven years follow-up.

Case 2: A 32-year-old woman with a gestational history of G3, P2, Ab1 and L2 was admitted to Mirza Koochak Khan Hospital, Tehran, Iran in September 2003 with nausea, vomiting and vaginal spotting. Sonography revealed a large necrotic mass in the left adnexa. Serum β-hCG level was 5500 mIU/mL and AFP level was within the normal range. After the surgery, she took 4 courses of chemotherapy with EMA-CE regimen. The level of β-hCG decreased to below the cut-off value. There has been no evidence of tumor recurrence during seven years follow-up.
Discussion
Choriocarcinoma of the ovary is a rare and aggressive tumor arising from germ cells, constituting less than 5% of all ovarian malignancies in Western countries. Ovarian choriocarcinoma can be divided into three groups: as a metastatic gestational choriocarcinoma due to a regressed or occult primary gestational choriocarcinoma in other parts of the genital tract (mostly uterine corpus); as a primary gestational choriocarcinoma arising from an ectopic ovarian pregnancy, and as a non-gestational germ cell tumor differentiating to trophoblastic components. All types secret β-hCG. However, β-hCG levels are usually lower in nongestational variants in comparison to gestational types. Monitoring of serum β-hCG can be a useful method in evaluating response to therapy. Serum β-hCG elevation leads to isosexual pseudopuberty in premenarchal patients, while patients in reproductive age usually present with menstrual abnormalities (mainly amenorrhea). Pure nongestational ovarian choriocarcinomas are extremely rare and highly malignant tumors frequently metastasizing through the lymphatics with intra-abdominal spread. Non-gestational type choriocarcinoma involves the patients with average age of 13 and is largely confined to females under 20. The presence of a well developed corpus luteum of pregnancy adjacent to the tumor may be indicative of a gestational origin. However, a search for paternal DNA in tumor allows a definite distinction between gestational and nongestational types. Tumors with gestational origin have paternal genomic structure while nongestational tumors have genomes of only maternal origin without any alleles from paternal origin. Since DNA polymorphism analysis is not a generally available laboratory technique, we couldn’t perform it on our cases.

Gestational ovarian choriocarcinomas have a better prognosis than their nongestational counterparts. However some studies suggest that surgical stage of pure ovarian choriocarcinoma may be more important determinant of clinical outcome compared to being of gestational or nongestational type. The two presented patients were in the forth decade of life and showed no elements of other germ cell tumors but well developed corpus luteum of pregnancy with hyaline globules and calcifications adjacent to tumor. This finding is in favor of the gestational origin of the tumors. However the possibility of pronounced corpus luteum due to high levels of β-hCG can not be excluded.

Conflict of Interests
Authors have no conflict of interests.
Authors' Contributions
NIM carried out the design, histological diagnosis and writing of manuscript. SS did the histological diagnosis and writing of manuscript. NS and PRM wrote and edited the manuscript. ZE and FY did the clinical diagnosis, treatment and follow-up of patients. All authors have read and approved the content of the manuscript.

References
1. Corakci A, Ozeren S, Ozkan S, Gurbuz Y, Ustun H, Yucesoy I. Pure nongestational choriocarcinoma of ovary. Arch Gynecol Obstet 2005;271(2):176-7.
2. Koo HL, Choi J, Kim KR, Kim JH. Pure non-gestational choriocarcinoma of the ovary diagnosed by DNA polymorphism analysis. Pathol Int 2006;56(1):613-6.
3. Yamamoto E, Ino K, Yamamoto T, Sumigama S, Nawa A, Nomura S, et al. A pure nongestational choriocarcinoma of the ovary diagnosed with short tandem repeat analysis: case report and review of the literature. Int J Gynecol Cancer 2007;17(1):254-8.
4. Tsujioka H, Hamada H, Miyakawa T, Hachissuga T, Kawarabayashi T. A pure nongestational choriocarcinoma of the ovary diagnosed with DNA polymorphism analysis. Gynecol Oncol 2003;89(3):540-2.
5. Lorigan PC, Colman RE, Hancock BW. The treatments of persistent trophoblastic disease using the Sheffield modification of chaing cross risk score. Proc Annu Meeting Am Soc Clin Oncol 1994;13:257.
6. Lorigan PC, Grierson AJ, Goepel JR, Coleman RE, Goyns MH. Gestational choriocarcinoma of the ovary diagnosed by analysis of tumor DNA. Cancer Letter 1996;104(1):27-30.
7. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 15-1977. N Engl J Med 1977;296(15):865-73.
8. Russell P, Farnsworth A. Surgical pathology of the ovaries. 2nd sub ed. Philadelphia: W.B. Saunders Company; 1997. p. 785-7.
9. Gerbie MV, Brewer JJ, Tamimi H. Primary choriocarcinoma of the ovary. Obstet Gynecol 1975;46(6):720-3.
10. Kaneta Y, Yoshiyama R, Inagaki N, Toyoshima K, Ito K, Nishino R, et al. Gestational choriocarcinoma whose responsible pregnancy was a complete hydatidiform mole identified by PCR analysis with new sequence tagged site primers. Jpn J Clin Oncol 1999;29(10):504-8.
11. Vance RP, Geisinger KR. Pure nongestational choriocarcinoma of the ovary report of a case. Cancer 1985;56(9):2321-5.
12. Axe SR, Klein VR, Woodruff JD. Choriocarcinoma of the ovary. Obstet Gynecol 1985;66(1):111-4.